GAMBARAN DOSIS TERAPI ARIPIPRAZOLE PASIEN SKIZOFRENIA DENGAN POLIMORFISME GEN DRD2 PADA TITIK RS6277 (C957T)
Abstract
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Sadock VA. 2008. Kaplan & Sadocks’s Concise Textbook of Clinical Psychiatry: Schizophrenia. 3rd ed. Philadelphia: Lippincott Williams & Wilkins.
Metrics GH. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet. 2018; 392: 1789-858.
Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophrenia Bulletin. 2018; 44(6): 1195–203.
Riskesdas. 2013. Laporan Hasil Riset Kesehatan Dasar 2013. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia. p. 163-4.
Lawford BR, Young RM, Swagell CD, Barnes M, Burton SC, Ward WK, et al. The C/C Genotype of the C957T Polymorphism of the Dopamine D2 Receptor is Associated with Schizophrenia. Schizophrenia Research. 2005; 73 (1): 31-7.
Brunton L, Hilal-Dandan R, Knollmann, B. 2018. Goodman & Gilman’s Pharmacological Basis of Therapeutics. 13th Edition. New York: McGraw Hill Education.
Bartolomeis AD, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies beyond Dopamine Receptor Antagonism. CNS Drugs. 2015, 29(9): 773–99.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology. Neuropsychopharmacology. 2003; 28(8): 1400-11.
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and Safety of Aripiprazole and Haloperidol versus Placebo in Patients with Schizophrenia and Schizoaffective Disorder. J Clin Psychiatry. 2002; 63 (9): 763-71.
Shen YC, Chen SF, Chen CH, Lin CCH, Chen SJ, Chen YJ, et al. Effects of DRD2/ANKK1 Gene Variations and Clinical Factors on Aripiprazole Ef?cacy in Schizophrenic Patients. Journal of Psychiatric Research. 2008; 43 (2009): 600-6.
Boland RJB, Verduin ML, Ruiz P. 2021. Kaplan & Sadock’s Synopsis of Psychiatry, 12th Edition. Philadelphia: Wolters Kluwer.
He M, Yan H, Duan ZX, Qu W, Gong HY, Fan ZL, et al. Genetic Distribution and Association Analysis of DRD2 Gene Polymorphisms with Major Depressive Disorder in the Chinese Han Population. Int J Clin Exp Pathol. 2013; 6(6): 1142-9.
Mueser KT, McGurk SR. Schizophrenia. Lancet. 2004; 363: 2063-2072.
Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and Safety of Aripiprazole and Haloperidol versus Placebo in Patients with Schizophrenia and Schizoaffective Disorder. J Clin Psychiatry. 2002; 63 (9): 763-71.
Sadock BJ, Sadock VA, Ruiz P. 2015. Kaplan & Sadocks’s Synopsis of Psychiatry: Schizophrenia Spectrum and Other Psychotic Disorders. 11rd ed. Philadelphia: Wolters Kluwer. p. 300-23.
Bartolomeis AD, Tomasetti C, Iasevoli F. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies beyond Dopamine Receptor Antagonism. CNS Drugs. 2015, 29(9): 773–99.
Vijayan NN, Bhaskaran S, Koshy LV, Natarajan C, Srinivas L, Nair CM, et al. Association of Dopamine Receptor Polymorphisms with Schizophrenia and Antipsychotic Response in a South Indian Population. Behavioral and Brain Functions. 2007; 3:34.
Katzung BG. 2018. Basic & Clinical Pharmacology: Antipsychotic Agents & Lithium. 4th ed. New York: McGraw Hill.
DOI: https://doi.org/10.32502/sm.v13i2.3825
Refbacks
- There are currently no refbacks.
Copyright (c) 2023 Miranti Dwi Dwi Hartanti
![Creative Commons License](http://licensebuttons.net/l/by-nc-sa/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.